Picture of Eurofins Scientific SE logo

ERF — Eurofins Scientific SE News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: Eurofins Updates FY 2024 Objectives

Oct 22 (Reuters) - Eurofins Scientific SE  EUFI.PA :
    * CONFIRMS PROFITABILITY AND CASH FLOW OBJECTIVES FOR 2024
LEADING
TO HIGHER PROFIT MARGINS IN SPITE OF THE IMPACT OF THE
POST-COVID RESET OF BIOPHARMA PIPELINES
    * REPORTED REVENUES IN 9M 2024 REACHED EUR 5,142M, +6.7%
VERSUS 9M
2023
    * CORE BUSINESS ORGANIC REVENUE GROWTH 5.2% IN 9M 2024
    * UPDATES FY 2024 OBJECTIVES
    * OBJECTIVES FOR FY 2024, ANNOUNCED AT FY 2023 RESULTS
PRESENTATION ON 27 FEBRUARY 2024, HAVE BEEN PARTLY UPDATED
    * EXPECTS FY 2024 ADJUSTED EBITDA OF €1.525BN-€1.575BN
    * OUTLOOK 2024 REVENUE CLOSE TO EUR 7 BILLION
    * EXPECTS FY 2024 FCFF OF €800M-€840M
    * TARGETS FINANCIAL LEVERAGE OF 1.5-2.5X IN MID-TERM
    * OUTLOOK: OBJECTIVES FOR FY 2027, ANNOUNCED ON 1 MARCH
2023,
REMAIN UNCHANGED
    * ON ACQUISITION OF SGS' CROP SCIENCE OPERATIONS: COMMITTED
TO
FOLLOWING THROUGH WITH TRANSACTION

Source text for Workspace:  ID:nBw73cXkQa 
Further company coverage:  EUFI.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Eurofins Scientific SE

See all news